1
|
Berardi G, Di Taranto A, Haouet N, Vita V, Palomba E, Rizzi G, Iammarino M. Monitoring of polyphosphate levels in animal source products collected in Italy by means of ion chromatography with suppressed conductivity detection. Ital J Food Saf 2023; 12:11110. [PMID: 38116373 PMCID: PMC10726398 DOI: 10.4081/ijfs.2023.11110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 02/27/2023] [Indexed: 12/21/2023] Open
Abstract
Polyphosphates (PPs) constitute a class of food additives widely used due to their ability to exercise different useful activities. The food safety concern about the use of PPs in food is both the possible non-declared addition and some health effects, such as bile duct stones, decrease in oligo-element absorption, and allergic reactions in susceptible people. In this study, an analytical method based on ion chromatography with conductivity detection was applied for the detection and quantification of PPs in 238 samples of animal-derived products such as meat, dairy, and fish products. A contribution to risk assessment was also included. The monitoring confirmed the absence of non-compliant results. All concentrations of PPs were indeed lower than the legal limits set in European Regulation No. 1333/2008. Moreover, no residue of PPs was detected (> limit of quantification: 0.09 g kg-1) in samples where it was not reported on the product label. No PPs were detected in mollusks, meat-based preparations, semi-ripened, unripened, and spun paste cheese, while they are widely used in surimi, with concentrations in the range of 0.1-0.5 g kg-1. The highest concentrations were quantified in a würstel sample (4.7±0.3 g kg-1) and a spreadable cheese sample (8.9±0.7 g kg-1). Considering that the high exposure scenario together with a very susceptible population group (toddlers) were taken into account for this risk exposure study and that the highest admissible daily intake obtained was equal to 10.4%, the assessment demonstrated that the actual use of PPs in food does not pose a risk for food safety.
Collapse
Affiliation(s)
- Giovanna Berardi
- Experimental Zooprophylactic Institute of Apulia and Basilicata, Foggia
| | | | - Naceur Haouet
- Food Control Laboratory, Experimental Zooprophylactic Institute of Umbria and Marche, Perugia, Italy
| | - Valeria Vita
- Experimental Zooprophylactic Institute of Apulia and Basilicata, Foggia
| | - Elena Palomba
- Experimental Zooprophylactic Institute of Apulia and Basilicata, Foggia
| | - Gianluca Rizzi
- Experimental Zooprophylactic Institute of Apulia and Basilicata, Foggia
| | - Marco Iammarino
- Experimental Zooprophylactic Institute of Apulia and Basilicata, Foggia
| |
Collapse
|
2
|
Grogg JB, Rizzi G, Gadient J, Wettstein MS, Affentranger A, Fankhauser CD, Eberli D, Poyet C. Prognostic value of pretreatment inflammatory markers in localised prostate cancer before radical prostatectomy. World J Urol 2023; 41:2693-2698. [PMID: 37749262 PMCID: PMC10581955 DOI: 10.1007/s00345-023-04569-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 08/06/2023] [Indexed: 09/27/2023] Open
Abstract
PURPOSE There is growing evidence of an association between inflammatory processes and cancer development and progression. In different solid tumor entities, a pronounced inflammatory response is associated with worse oncological outcome. In this study, we aim to evaluate the prognostic role of clinically established pretreatment inflammatory markers in patients with localised prostate cancer (PCa) before radical prostatectomy (RP). METHODS A total of 641 men met our inclusion criteria and were followed prospectively for a median of 2.85 years. Univariable logistic and Cox regression analysis were performed to analyse associations between preoperative inflammatory markers and tumor characteristics, and biochemical recurrence free survival (BRFS). RESULTS Median age at RP was 64 years. Gleason Score (GS) 7a (263, 41%) was the most prevalent histology, whereas high-risk PCa (≥ GS 8) was present in 156 (24%) patients. Lympho-nodal metastasis and positive surgical margin (PSM) were detected in 69 (11%) and 180 (28%) patients, respectively. No statistically relevant association could be shown between pretreatment inflammatory markers with worse pathological features like higher tumor stage or grade, nodal positive disease or PSM (for all p > 0.05). Additionally, pretreatment inflammatory markers were not associated with a shorter BRFS (p > 0.05). Known risk factors (tumor grade, tumor stage, nodal positivity and positive surgical margins) were all associated with a shorter BRFS (for all p < 0.0001). CONCLUSION In this large prospective cohort, preoperative inflammatory markers were not associated with worse outcome.
Collapse
Affiliation(s)
- Josias Bastian Grogg
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland.
| | - Gianluca Rizzi
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Jana Gadient
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Marian Severin Wettstein
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Andres Affentranger
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Christian Daniel Fankhauser
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Daniel Eberli
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| | - Cédric Poyet
- Department of Urology, University Hospital of Zurich, University of Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland
| |
Collapse
|
3
|
Poyet C, Scherer TP, Kunz M, Wanner M, Korol D, Rizzi G, Kaufmann B, Rohrmann S, Hermanns T. Retrospective analysis of the uptake of active surveillance for low-risk prostate cancer in Zurich, Switzerland. Swiss Med Wkly 2023; 153:40103. [PMID: 37499067 DOI: 10.57187/smw.2023.40103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/29/2023] Open
Abstract
OBJECTIVES Active surveillance for low-risk prostate cancer closely monitors patients conservatively instead of the pursuit of active treatment to reduce overtreatment of insignificant disease. Since 2009, active surveillance has been recommended as the primary management option in the European Association of Urology guidelines for low-risk disease. The present study aimed to investigate the use and uptake of active surveillance over 10 years in our certified prostate cancer centre (University Hospital of Zurich) compared with those derived from the cancer registry of the canton of Zurich, Switzerland. MATERIALS AND METHODS We retrospectively identified all men diagnosed with low-risk prostate cancer at our institution and from the cancer registry of the canton of Zurich from 2009 to 2018. The primary treatment of each patient was recorded. Descriptive statistics were used to analyze the use of different treatments in our centre. The results were compared with those derived from the cancer registry. RESULTS A total of 3393 men with low-risk prostate cancer were included in this study (University Hospital of Zurich: n = 262; cancer registry: n = 3131). In the University Hospital of Zurich and cancer registry cohorts, 146 (55.7%) and 502 (16%) men underwent active surveillance, respectively. The proportions of local treatment [115 (43.9%) vs 2220 (71%)] and androgen deprivation therapy [0 (0%) vs 43 (1.4%)] were distinctly lower in the University Hospital of Zurich cohort than in the cancer registry cohort. The uptake of active surveillance over the years was high in the University Hospital of Zurich cohort (35.4% in 2009 and 88.2% in 2018) but only marginal in the cancer registry cohort (12.2% in 2009 and 16.2% in 2018). CONCLUSION Despite clear guideline recommendations, active surveillance for low-risk prostate cancer is still widely underused. Our analysis showed that access to a certified interdisciplinary tumour board significantly increases the use of active surveillance.
Collapse
Affiliation(s)
- Cédric Poyet
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
| | - Thomas Paul Scherer
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
| | - Mirjam Kunz
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- Cancer registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, University of Zurich, Switzerland
| | - Miriam Wanner
- Cancer registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, University of Zurich, Switzerland
| | - Dimitri Korol
- Cancer registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, University of Zurich, Switzerland
| | - Gianluca Rizzi
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
| | - Basil Kaufmann
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
| | - Sabine Rohrmann
- Cancer registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, University of Zurich, Switzerland
| | - Thomas Hermanns
- Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
| |
Collapse
|
4
|
Rizzi G, Neff P, Madeo A. Metamaterial shields for inner protection and outer tuning through a relaxed micromorphic approach. Philos Trans A Math Phys Eng Sci 2022; 380:20210400. [PMID: 35858081 DOI: 10.1098/rsta.2021.0400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Accepted: 02/07/2022] [Indexed: 06/15/2023]
Abstract
In this paper, a coherent boundary value problem to model metamaterials' behaviour based on the relaxed micromorphic model is established. This boundary value problem includes well-posed boundary conditions, thus disclosing the possibility of exploring the scattering patterns of finite-size metamaterial specimens. Thanks to the simplified model's structure (few frequency- and angle-independent parameters), we are able to unveil the scattering metamaterial's response for a wide range of frequencies and angles of propagation of the incident wave. These results are an important stepping stone towards the conception of more complex large-scale meta-structures that can control elastic waves and recover energy. This article is part of the theme issue 'Wave generation and transmission in multi-scale complex media and structured metamaterials (part 1)'.
Collapse
Affiliation(s)
- Gianluca Rizzi
- Faculty of Architecture and Civil Engineering, TU Dortmund, August-Schmidt-Str. 8, 44227 Dortmund, Germany
| | - Patrizio Neff
- Head of Chair for Nonlinear Analysis and Modelling, Fakultät für Mathematik, Universität Duisburg-Essen, Thea-Leymann-Straße 9, 45127 Essen, Germany
| | - Angela Madeo
- Head of Chair of Continuum Mechanics, Faculty of Architecture and Civil Engineering, TU Dortmund, August-Schmidt-Str. 8, 44227 Dortmund, Germany
| |
Collapse
|
5
|
Arcara G, Pezzetta R, Benavides-Varela S, Rizzi G, Formica S, Turco C, Piccione F, Semenza C. Magnetoencephalography reveals differences in brain activations for fast and slow responses to simple multiplications. Sci Rep 2021; 11:20296. [PMID: 34645843 PMCID: PMC8514455 DOI: 10.1038/s41598-021-97927-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 08/17/2021] [Indexed: 11/30/2022] Open
Abstract
Despite decades of studies, it is still an open question on how and where simple multiplications are solved by the brain. This fragmented picture is mostly related to the different tasks employed. While in neuropsychological studies patients are asked to perform and report simple oral calculations, neuroimaging and neurophysiological studies often use verification tasks, in which the result is shown, and the participant must verify the correctness. This MEG study aims to unify the sources of evidence, investigating how brain activation unfolds in time using a single-digit multiplication production task. We compared the participants' brain activity-focusing on the parietal lobes-based on response efficiency, dividing their responses in fast and slow. Results showed higher activation for fast, as compared to slow, responses in the left angular gyrus starting after the first operand, and in the right supramarginal gyrus only after the second operand. A whole-brain analysis showed that fast responses had higher activation in the right dorsolateral prefrontal cortex. We show a timing difference of both hemispheres during simple multiplications. Results suggest that while the left parietal lobe may allow an initial retrieval of several possible solutions, the right one may be engaged later, helping to identify the solution based on magnitude checking.
Collapse
Affiliation(s)
- Giorgio Arcara
- grid.492797.6IRCCS San Camillo Hospital, Via Alberoni 70, Lido, 30126 Venice, Italy
| | - Rachele Pezzetta
- grid.492797.6IRCCS San Camillo Hospital, Via Alberoni 70, Lido, 30126 Venice, Italy
| | - S. Benavides-Varela
- grid.5608.b0000 0004 1757 3470Department of Developmental Psychology and Socialization, University of Padova, Padua, Italy ,grid.5608.b0000 0004 1757 3470Department of Neuroscience (Padova Neuroscience Centre), University of Padova, Padua, Italy
| | - G. Rizzi
- grid.5608.b0000 0004 1757 3470Department of Neuroscience (Padova Neuroscience Centre), University of Padova, Padua, Italy
| | - S. Formica
- grid.5342.00000 0001 2069 7798Department of Experimental Psychology, Ghent University, Ghent, Belgium
| | - C. Turco
- grid.492797.6IRCCS San Camillo Hospital, Via Alberoni 70, Lido, 30126 Venice, Italy
| | - F. Piccione
- grid.5608.b0000 0004 1757 3470Riabilitazione, Azienda Ospedale - Università di Padova, Regione Veneto, Italy
| | - C. Semenza
- grid.5608.b0000 0004 1757 3470Department of Neuroscience (Padova Neuroscience Centre), University of Padova, Padua, Italy
| |
Collapse
|
6
|
Schmid FA, Poyet C, Rizzi G, Gomolka RS, Donati OF, Hötker AM, Eberli D. Dynamic contrast enhancement in prostate MRI as predictor of erectile function and recovery after radical prostatectomy. Aging Male 2020; 23:1518-1526. [PMID: 33252281 DOI: 10.1080/13685538.2020.1815695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
PURPOSE To analyze routine preoperative prostate MRI to predict erectile function (EF) before and after radical prostatectomy (RP). METHODS Patients who underwent RP with an existing preoperative MRI including dynamic contrast-enhanced images and completed International Index of Erectile Function (IIEF-5) questionnaires at baseline and 12 months postoperative. They were divided into four erectile dysfunction (ED) groups according to preoperative IIEF-5 score. The perfusion quality was measured in the peripheral zone of the prostate by the ratio of signal increase 120 s after wash-in of contrast agent (Ratio120) in preoperative MRI and compared between the ED groups. RESULTS Ratio120 showed differences among the preoperative ED groups (p = .020) in 97 patients. According to IIEF-5 at 12 months postoperative, 43 patients were dichotomized into "no to mild" (≥17 points) and "moderate to severe" (≤16) ED groups. Ratio120 revealed differences among the postoperative ED groups (128.84% vs. 101.95%; p = .029) and stayed an independent predictor for ED in the multivariable regression analysis (adjusted for age, nerve-sparing and preoperative IIEF-5). ROC curves demonstrated an additional diagnostic benefit. CONCLUSIONS Preoperative MRI of the prostate may be used for the prediction of EF and postsurgical recovery after RP. This may serve as important tool in preoperative patient counseling and management of expectations.
Collapse
Affiliation(s)
- Florian A Schmid
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Cédric Poyet
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Gianluca Rizzi
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| | - Richard S Gomolka
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland
| | - Olivio F Donati
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland
| | - Andreas M Hötker
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland
| | - Daniel Eberli
- Department of Urology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
7
|
Rizzi G, Silva-Zacarin E, Oliveira C, Costa M, Salla R, Abdalla F. Morphological characterization of the gonads of bullfrog tadpoles (Lithobates catesbeianus). ACTA ACUST UNITED AC 2018. [DOI: 10.4322/jms.074214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Abstract
Introduction: This work describes various aspects of early gonadal development of female and male in pre-metamorphic tadpoles (Lithobates catesbeianus) at Gosner stage 25. Materials and Methods: Ovaries and testicles were prepared for routine light microscopy for morphological study and for acridine orange technique fluroescent microscopy for observation of RNA cytoplasm activity. Results: The results showed that female gonads at Gosner stage 25 predominated primary and secondary oogonias, as well as primary, secondary and tertiary oocytes. The developing testicle presented primary spermatogonia (I or A) and secondary spermatogonia (II or B), and as well as primary and secondary spermatocyte. All this cell phases were morphologically characterized and the cell sizes measured. In pre-metamorphic testes the somniferous duct are not developed and the vasa deferentia is opened. Conclusion: At this point, it was possible differentiate ovary from testes does not for the gonadal cells, but for the general anatomy of the organs, being the ovary a spheroid structure and the testicle an elongated tubule.
Collapse
Affiliation(s)
- G. Rizzi
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
- Universidade Estadual “Júlio de Mesquita Filho” - UNESP, Campus de Rio Claro, Avenida 24ª, 1515, CEP 13506-900, Rio Claro, SP, Brasil
| | - E. Silva-Zacarin
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
| | - C. Oliveira
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
| | - M. Costa
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
| | - R. Salla
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
| | - F. Abdalla
- Laboratório de Biologia Estrutural e Funcional - LABEF, Universidade Federal de São Carlos - UFSCar, Campus Sorocaba, Rodovia João Leme dos Santos, Km 110, CEP 18052-780, Sorocaba, SP, Brasil
- Universidade Estadual “Júlio de Mesquita Filho” - UNESP, Campus de Rio Claro, Avenida 24ª, 1515, CEP 13506-900, Rio Claro, SP, Brasil
| |
Collapse
|
8
|
Mortezavi A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, Hermanns T, Eberli D. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. J Urol 2018; 200:309-318. [DOI: 10.1016/j.juro.2018.02.067] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/12/2018] [Indexed: 01/29/2023]
Affiliation(s)
- Ashkan Mortezavi
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Olivia Märzendorfer
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Olivio F. Donati
- Institutes of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Gianluca Rizzi
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Niels J. Rupp
- Surgical Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Marian S. Wettstein
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Oliver Gross
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Tullio Sulser
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Thomas Hermanns
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Daniel Eberli
- Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| |
Collapse
|
9
|
Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla R, Karthaus M. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol 2018; 29:1535-1540. [DOI: 10.1093/annonc/mdy169] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Abstract
Three cases of connective tissue tumors causing hypophosphatemic osteomalacia are reported and the literature is reviewed. In two of our patients the tumors were completely excised with total disappearance of the symptoms. In one case a total excision was not possible and the symptoms of this patient have not completely disappeared. The substance responsible for the syndrome has not been identified yet, but probably interferes with vitamin D renal hy-droxylation, thus causing osteomalacia. As more than 30 per cent of cases of this condition have been reported in the last 5 years, it is suggested that these tumors are more frequent than previously believed.
Collapse
Affiliation(s)
- M Papotti
- Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Italia
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
One of the most important factors determining the degree of tissue interaction of an implanted device is the property of its surface. Thus, great importance is given to chemical and morphological characteristics of biomaterial surfaces to improve biocompatibility, cell migration, proliferation and differentiation, mechanical stability and endogenous tissue ingrowth. In order to obtain new and healing stimulating properties, it is possible to apply a coating or more generally a surface treatment to the surface of a prosthetic device. One of the most versatile methods for coating is thermal spray technology. This paper considers the principle of thermal spray processes and their application in the biomedical field, namely the coatings used for orthopedic prostheses and dental implants. Among thermal spray processes, plasma spray as well as High Velocity Oxygen Fuel (HVOF) processes will be particularly considered and their most important aspects will be illustrated.
Collapse
Affiliation(s)
- G Rizzi
- Biocoatings Srl, Rubbiano di Solignano, Parma, Italy
| | | | | | | |
Collapse
|
12
|
Schwartzberg L, Andric Z, Kowalski D, Voisin D, Rizzi G, Karthaus M. Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Rizzi G, Startseva X, Wolfrum M, Lüscher T, Ruschitzka F, Fröhlich G, Enseleit F. Unfavorable Donor Pretransplant APACHE II, SAPS II, and SOFA Scores Are Not Associated With Outcome: Implications for Heart Transplant Donor Selection. Transplant Proc 2016; 48:2582-2587. [DOI: 10.1016/j.transproceed.2016.06.059] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 03/01/2016] [Accepted: 06/06/2016] [Indexed: 12/21/2022]
|
14
|
Rugo HS, Aapro M, Rizzi G. Abstract P1-10-06: Nausea control and quality-of-life benefit with NEPA, the first combination antiemetic agent, in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients (pts) with breast cancer (BC) are at high risk for developing chemotherapy-induced nausea and vomiting (CINV) due to the emetogenicity of chemotherapy (often AC-based) and predisposing risk factors including young age and female gender. For pts receiving AC, antiemetic guidelines recommend prophylactic administration of an NK1 receptor antagonist (RA), a 5-HT3 RA, and dexamethasone (DEX). NEPA is the first fixed combination agent approved in oncology; comprised of a highly selective NK1 receptor antagonist (RA), netupitant (300 mg), and the pharmacologically/clinically distinct 5-HT3 RA, palonosetron (PALO 0.50 mg). NEPA has shown superior complete response (no emesis/no rescue use) rates compared with oral PALO in a Phase 3 trial in pts receiving AC (Aapro, Ann Oncol 2014) and in that study's BC subset. Despite progress in prevention of vomiting, nausea control remains suboptimal, particularly in the delayed phase (days 2-5), and debate exists whether NK1 RAs improve nausea control. The objective of this post-hoc analysis was to evaluate whether NEPA showed nausea and associated quality-of-life (QOL) benefits in the subset of patients with BC in this trial.
Methods: The subset of chemotherapy-naïve BC pts from this multinational, randomized, double-blind Phase 3 study were included in this analysis. Patients received either a single dose of NEPA or oral PALO prior to AC along with oral DEX 12 mg (NEPA) or 20 mg (PALO). No significant nausea (NSN: max <25 mm on 100 mm visual analog scale) rates in the acute (0-24h), delayed (25-120h) and overall (0-120h) phases following chemotherapy during cycles 1-4 were calculated. QOL was assessed by the Functional Living Index—Emesis (FLIE) during cycle 1 overall phase; the percentage of pts with "no impact on daily life" (NIDL) was calculated. Comparisons between groups were performed using a Cochran-Maentel-Haenszel test.
Results: 1412 patients with BC were included for a total of 5839 AC cycles. NSN rates were similar for both groups in the acute phase, superior for NEPA during cycles 1, 2 and 4 in the delayed phase, and superior for NEPA during cycles 1-4 in the overall phase.
Overall NSN (0-120h)NEPA + DEXOral PALO + DEXP ValueCycle 174.2% (N = 708)68.5% (N = 704)0.016Cycle 277.0% (N = 621)71.1% (N = 636)0.015Cycle 378.2% (N = 586)72.7% (N = 594)0.027Cycle 479.9% (N = 542)74.9% (N = 550)0.040
This corresponded with a significantly greater proportion of NEPA patients reporting NIDL compared with PALO due to nausea (71% vs 65%; p=0.007) in cycle 1.
Conclusions: While other NK1RAs have not consistently shown benefit in improving nausea control over 5-HT3RA + DEX, in this study NEPA significantly improved prevention of nausea over oral PALO in BC patients receiving AC. In addition, NEPA was superior to PALO in reducing the negative impact of nausea on patients' daily functioning. As the first fixed antiemetic drug combination, NEPA is highly effective and offers the convenience of a single dose administered with DEX on Day 1 only.
Citation Format: Rugo HS, Aapro M, Rizzi G. Nausea control and quality-of-life benefit with NEPA, the first combination antiemetic agent, in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-06.
Collapse
Affiliation(s)
- HS Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Clinique de Genolier, Genolier, Switzerland; Helsinn Healthcare, SA, Lugano, Switzerland
| | - M Aapro
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Clinique de Genolier, Genolier, Switzerland; Helsinn Healthcare, SA, Lugano, Switzerland
| | - G Rizzi
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Clinique de Genolier, Genolier, Switzerland; Helsinn Healthcare, SA, Lugano, Switzerland
| |
Collapse
|
15
|
Aapro M, Rugo H, Rizzi G. P182 NEPA, a new combination antiemetic, exhibits sustained efficacy over repeated chemotherapy cycles. Breast 2015. [DOI: 10.1016/s0960-9776(15)70221-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
16
|
Jahn P, Jordan K, Rizzi G. 173 Does preventing nausea correlate with an improvement in functioning for patients with cancer? Evaluation of NEPA, a novel fixed-dose antiemetic combination. Eur J Oncol Nurs 2014. [DOI: 10.1016/s1462-3889(14)70190-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Aapro M, Gralla R, Karthaus M, Schwartzberg L, Rossi G, Rizzi G, Borroni M, Palmas M, Rugo H, Jordan K. Multicycle Efficacy and Safety of Nepa, a Fixed-Dose Antiemetic Combination of Netupitant and Palonosetron, in Patients Receiving Chemotherapy of Varying Emetogenicity. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Jahn P, Jordan K, Rizzi G. 75 Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron). Eur J Oncol Nurs 2014. [DOI: 10.1016/s1462-3889(14)70093-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
19
|
Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25:1333-1339. [PMID: 24631949 PMCID: PMC4071753 DOI: 10.1093/annonc/mdu096] [Citation(s) in RCA: 139] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Accepted: 02/21/2014] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Safe, effective and convenient antiemetic regimens that preserve benefit over repeated cycles are needed for optimal supportive care during cancer treatment. NEPA, an oral fixed-dose combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron (PALO), a distinct 5-HT3 RA, was shown to be superior to PALO in preventing chemotherapy-induced nausea and vomiting after a single cycle of highly (HEC) or moderately (MEC) emetogenic chemotherapy in recent trials. This study was designed primarily to assess the safety but also to evaluate the efficacy of NEPA over multiple cycles of HEC and MEC. PATIENTS AND METHODS This multinational, double-blind, randomized phase III study (NCT01376297) in 413 chemotherapy-naïve patients evaluated a single oral dose of NEPA (NETU 300 mg + PALO 0.50 mg) given on day 1 with oral dexamethasone (DEX). An oral 3-day aprepitant (APR) regimen + PALO + DEX was included as a control (3:1 NEPA:APR randomization). In HEC, DEX was administered on days 1-4 and in MEC on day 1. Safety was assessed primarily by adverse events (AEs), including cardiac AEs; efficacy by complete response (CR: no emesis, no rescue). RESULTS Patients completed 1961 total chemotherapy cycles (76% MEC, 24% HEC) with 75% completing ≥4 cycles. The incidence/type of AEs was comparable for both groups. Most frequent NEPA-related AEs included constipation (3.6%) and headache (1.0%); there was no indication of increasing AEs over multiple cycles. The majority of AEs were mild/moderate and there were no cardiac safety concerns based on AEs and electrocardiograms. The overall (0-120 h) CR rates in cycle 1 were 81% and 76% for NEPA and APR + PALO, respectively, and antiemetic efficacy was maintained over repeated cycles. CONCLUSIONS NEPA, a convenient single oral dose antiemetic targeting dual pathways, was safe, well tolerated and highly effective over multiple cycles of HEC/MEC.
Collapse
Affiliation(s)
- R J Gralla
- Department of Medical Oncology, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, USA.
| | - S M Bosnjak
- Department of Supportive Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - A Hontsa
- Chernivtsi Regional Cancer Hospital, Chernivtsi, Ukraine
| | - C Balser
- OnkoNet Marburg GmbH, Marburg, Germany
| | - G Rizzi
- Department of Statistics and Data Management
| | - G Rossi
- Department of Corporate Clinical Development, Helsinn Healthcare SA, Lugano, Switzerland
| | - M E Borroni
- Department of Corporate Clinical Development, Helsinn Healthcare SA, Lugano, Switzerland
| | - K Jordan
- Department of Hematology and Oncology, University of Halle-Wittenberg, Halle, Germany
| |
Collapse
|
20
|
Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25:1340-1346. [PMID: 24608196 PMCID: PMC4071755 DOI: 10.1093/annonc/mdu110] [Citation(s) in RCA: 161] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Revised: 03/01/2014] [Accepted: 03/04/2014] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK1) receptor antagonist (RA) and palonosetron (PALO), a pharmacologically and clinically distinct 5-hydroxytryptamine type 3 (5-HT3) RA. This study was designed to determine the appropriate clinical dose of NETU to combine with PALO for evaluation in the phase 3 NEPA program. PATIENTS AND METHODS This randomized, double-blind, parallel group study in 694 chemotherapy naïve patients undergoing cisplatin-based chemotherapy for solid tumors compared three different oral doses of NETU (100, 200, and 300 mg) + PALO 0.50 mg with oral PALO 0.50 mg, all given on day 1. A standard 3-day aprepitant (APR) + IV ondansetron (OND) 32 mg regimen was included as an exploratory arm. All patients received oral dexamethasone on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) during the overall (0-120 h) phase. RESULTS All NEPA doses showed superior overall CR rates compared with PALO (87.4%, 87.6%, and 89.6% for NEPA100, NEPA200, and NEPA300, respectively versus 76.5% PALO; P < 0.050) with the highest NEPA300 dose studied showing an incremental benefit over lower NEPA doses for all efficacy endpoints. NEPA300 was significantly more effective than PALO and numerically better than APR + OND for all secondary efficacy endpoints of no emesis, no significant nausea, and complete protection (CR plus no significant nausea) rates during the acute (0-24 h), delayed (25-120 h), and overall phases. Adverse events were comparable across groups with no dose response. The percent of patients developing electrocardiogram changes was also comparable. CONCLUSIONS Each NEPA dose provided superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with PALO following highly emetogenic chemotherapy; however, NEPA300 was the best dose studied, with an advantage over lower doses for all efficacy endpoints. The combination of NETU and PALO was well tolerated with a similar safety profile to PALO and APR + OND.
Collapse
Affiliation(s)
- P J Hesketh
- Lahey Hospital & Medical Center, Burlington, USA.
| | - G Rossi
- Corporate Clinical Development and Statistics & Data Management, Helsinn Healthcare SA, Lugano, Switzerland
| | - G Rizzi
- Corporate Clinical Development and Statistics & Data Management, Helsinn Healthcare SA, Lugano, Switzerland
| | - M Palmas
- Corporate Clinical Development and Statistics & Data Management, Helsinn Healthcare SA, Lugano, Switzerland
| | - A Alyasova
- Federal State Institution, Privolzhsky District Medical Center under the Federal Medical-Biological Agency of Russia, Nizhny Novgorod, Russia
| | - I Bondarenko
- Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine
| | - A Lisyanskaya
- City Clinical Oncology Dispensary, Saint Petersburg, Russia
| | - R J Gralla
- Albert Einstein College of Medicine, Bronx, USA
| |
Collapse
|
21
|
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25:1328-1333. [PMID: 24603643 PMCID: PMC4071754 DOI: 10.1093/annonc/mdu101] [Citation(s) in RCA: 178] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Accepted: 02/25/2014] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of chemotherapy-induced nausea and vomiting (CINV). NEPA is a new oral fixed-dose combination of 300 mg netupitant, a highly selective NK1 receptor antagonist (RA) and 0.50 mg palonosetron (PALO), a pharmacologically and clinically distinct 5-HT3 RA, which targets dual antiemetic pathways. PATIENTS AND METHODS This multinational, randomized, double-blind, parallel group phase III study (NCT01339260) in 1455 chemotherapy-naïve patients receiving moderately emetogenic (anthracycline-cyclophosphamide) chemotherapy evaluated the efficacy and safety of a single oral dose of NEPA versus a single oral dose (0.50 mg) of PALO. All patients also received oral dexamethasone (DEX) on day 1 only (12 mg in the NEPA arm and 20 mg in the PALO arm). The primary efficacy end point was complete response (CR: no emesis, no rescue medication) during the delayed (25-120 h) phase in cycle 1. RESULTS The percentage of patients with CR during the delayed phase was significantly higher in the NEPA group compared with the PALO group (76.9% versus 69.5%; P = 0.001), as were the percentages in the overall (0-120 h) (74.3% versus 66.6%; P = 0.001) and acute (0-24 h) (88.4% versus 85.0%; P = 0.047) phases. NEPA was also superior to PALO during the delayed and overall phases for all secondary efficacy end points of no emesis, no significant nausea and complete protection (CR plus no significant nausea). NEPA was well tolerated with a similar safety profile as PALO. CONCLUSIONS NEPA plus a single dose of DEX was superior to PALO plus DEX in preventing CINV following moderately emetogenic chemotherapy in acute, delayed and overall phases of observation. As a fixed-dose antiemetic drug combination, NEPA along with a single dose of DEX on day 1 offers guideline-based prophylaxis with a convenient, single-day treatment.
Collapse
Affiliation(s)
- M Aapro
- Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
| | - H Rugo
- Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
| | - G Rossi
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - G Rizzi
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - M E Borroni
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - I Bondarenko
- Department of Oncology, Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine
| | | | | | - S Cardona-Huerta
- Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey, Mexico
| | - V Lorusso
- National Cancer Institute Giovanni Paolo II, Bari, Italy
| | - M Karthaus
- Department of Hematology, Oncology and Palliative Medicine, Staedt. Klinikum Neuperlach and Harlaching, München, Germany
| | | | - S Grunberg
- Fletcher Allen Health Care, Burlington, USA
| |
Collapse
|
22
|
Locatelli F, Pozzi M, Avantaggiato P, Lanfranchi M, Tufarulo L, Amorelli V, Rizzi G, Radice S, Galbiati S, Clementi E, Strazzer S. Pharyngeal spasticity due to dantrolene. J Clin Pharm Ther 2014; 39:449-51. [PMID: 24725261 DOI: 10.1111/jcpt.12161] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 03/06/2014] [Indexed: 11/27/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Dantrolene can be combined with baclofen to better treat spasticity, but may cause muscular weakness and dysphagia. We instead describe a pharyngeal spasm due to dantrolene. CASE SUMMARY A 12-year-old male received dantrolene 3 mg/kg/day in adjunct to baclofen 2 mg/kg/day, to improve spasticity. After 5 days of full-dose dantrolene, his dysphagia worsened and he developed pharyngeal spasm. Dantrolene was suspected for an adverse reaction and removed. The patient subsequently improved. WHAT IS NEW AND CONCLUSION Causality analysis determined a probable relationship between dantrolene and pharyngeal spasm. This may be due to direct muscle contraction by dantrolene, an effect seen previously in vitro.
Collapse
Affiliation(s)
- F Locatelli
- Scientific Institute, IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Rugo HS, Rossi G, Rizzi G, Borroni ME, Lorusso V, Karthaus M, Bondarenko I, Sarosiek TJ, Aapro MS. Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Breast cancer (BC) patients receiving anthracycline-cyclophosphamide (AC) chemotherapy (CT) are at risk for developing CINV due not only to the emetogenicity of the CT but also to young age and gender. As recommended by international antiemetic guidelines, targeting multiple molecular pathways involved in emesis related to AC is important for maximizing control of CINV and improving the functional status of BC patients during CT. NEPA is a fixed-dose combination of netupitant (NETU), a highly-selective NK1 receptor antagonist (RA), and palonosetron (PALO), a pharmacologically distinct 5-HT3 RA, that targets dual antiemetic pathways with a convenient single day dose.
Methods:
This was a multinational, randomized, double-blind, phase 3 study evaluating the efficacy and safety of a single oral dose of NEPA (NETU 300 mg + PALO 0.50 mg) versus a single oral 0.50 mg dose of PALO in chemotherapy-naïve patients receiving AC. All patients received oral dexamethasone (DEX) on day 1 (12 mg NEPA arm; 20 mg PALO arm). The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) in the delayed phase, 25-120h after CT. The Functional Living Index-Emesis (FLIE) questionnaire with a 5-day recall period was used to assess the impact of CINV on patients’ daily lives as a secondary endpoint. The FLIE consists of 9 nausea-specific (nausea domain) and 9 vomiting-specific (vomiting domain) items that address the effect of nausea and vomiting on daily life. Each item is scored on a 7-point 100 mm visual analog scale with anchors of “none/not at all” and “a great deal”. The proportion of patients with an average item score >6 reflecting “no impact on daily life” (NIDL) (ie, total FLIE score >108, nausea/vomiting domain score >54) was compared for NEPA vs PALO using a Cochran-Maentel-Haenszel test stratified by age class and region.
Results:
1455 patients with a mean age of 54 were randomized to receive NEPA or PALO. Treatment groups were similar; 98% were females with BC (97%).
As previously reported (ASCO 2013), NEPA showed superior CR rates compared to PALO for the acute 0-24h (88% vs 85%; p = 0.047), delayed (77% vs 70%; p = 0.001) and overall 0-120h (74% vs 67%; p = 0.001) phases.
A greater proportion of NEPA-treated patients reported NIDL for nausea, vomiting and combined domains compared to PALO.
% Patients with NIDL (Overall 0-120h)NEPA (N = 724)PALO (N = 725)p-valueNausea domain72%66%0.015Vomiting domain90%84%0.001Overall combined79%72%0.0056 patients excluded who did not receive AC or study drug
The adverse event (AE) profile was comparable between groups. Most frequently reported treatment-related AEs for NEPA and PALO, respectively, were headache (3.3%, 3.0%) and constipation (2.1%, 2.1%).
Conclusions:
In this large Phase 3 study of predominantly females with BC receiving AC, NEPA was superior to PALO in preventing CINV and reducing the negative impact of CINV on patients’ daily lives. As a fixed-dose antiemetic drug combination including an NK1 RA and 5-HT3 RA, NEPA offers improved efficacy over PALO alone, with a convenient single-day dose, and oral DEX only on day 1.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-01.
Collapse
Affiliation(s)
- HS Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - G Rossi
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - G Rizzi
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - ME Borroni
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - V Lorusso
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - M Karthaus
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - I Bondarenko
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - TJ Sarosiek
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - MS Aapro
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| |
Collapse
|
24
|
Rustichelli F, Romanzetti S, Dubini B, Girardin E, Raven C, Snigirev A, Rizzi G. Phase-contrast microtomography of thin biomaterials. J Mater Sci Mater Med 2004; 15:1053-1057. [PMID: 15448414 DOI: 10.1023/b:jmsm.0000042692.34537.8e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Phase-contrast microtomography, performed at the beamline ID 22 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France), is demonstrated for high-resolution 3-D imaging of a hydroxyapatite sample. The technique, which relies on phase contrast imaging, gives the possibility to observe features inside samples with negligible absorption contrast. The positive results obtained suggest a possible future investigation of the influence of the distribution of pores and defects inside biomaterial coatings, on the growth of osteoblast cells.
Collapse
Affiliation(s)
- F Rustichelli
- Istituto di Scienze Fisiche, Università degli Studi di Ancona and INFM, Via P. Ranieri 65, 60131 Ancona, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Diegele E, Krüssmann R, Malang S, Norajitra P, Rizzi G. Modular He-cooled divertor for power plant application. Fusion Engineering and Design 2003. [DOI: 10.1016/s0920-3796(03)00257-6] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Savarino L, Fini M, Ciapetti G, Cenni E, Granchi D, Baldini N, Greco M, Rizzi G, Giardino R, Giunti A. Biologic effects of surface roughness and fluorhydroxyapatite coating on osteointegration in external fixation systems: an in vivo experimental study. J Biomed Mater Res A 2003; 66:652-61. [PMID: 12918049 DOI: 10.1002/jbm.a.10018] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The concomitant influence of surface roughness and fluorhydroxyapatite (FHA) coating of titanium (Ti) implants on bone response was investigated. For this purpose, titanium screw-shaped implants with a lower degree (Y371) and a higher degree (TiPore300) of surface roughness, coated with FHA and uncoated, were transversally inserted into the diaphyses of sheep tibiae for 12 weeks. Four sheep received Y371 (group A) and Y371 + FHA (group B) screws and four sheep received TiPore300 (group C) and TiPore300 + FHA (group D) screws. For each type of material, the morphology and microstructure of implant-facing bone were evaluated. The host bone of each tibia was used as a control. In all groups the bone tissue did not reach a complete maturation. The higher degree of roughness, perhaps due to an excessive irregularity of the surface, induced the worst osteointegration: a fibrous tissue layer between screw and new bone tissue was often present. Nevertheless, as viewed by XRD, no crystallographic change of the apatite lattice was observed in any of the implants. In contrast, the microhardness value, an index of bone mineralization, was higher in the uncoated screws and decreased progressively in the following order: group C > group A > group B > group D. The association of plasma spraying with roughness treatment constitutes a complex system that seems to interfere with bone mineralization. A chemical change of the surface, perhaps with more Ti release or more coating degradation, could be responsible for such impairment. The authors emphasize the necessity for simultaneous evaluation of surface topography and chemistry as well as an improvement in plasma-spraying and post-processing techniques and in standard procedures for materials characterization.
Collapse
Affiliation(s)
- L Savarino
- Laboratorio di Fisiopatologia degli Impianti Ortopedici, Istituti Ortopedici Rizzoli, Bologna and Università di Bologna, Via di Barbiano 1/10, 40136 Bologna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Fini M, Savarino L, Nicoli Aldini N, Martini L, Giavaresi G, Rizzi G, Martini D, Ruggeri A, Giunti A, Giardino R. Biomechanical and histomorphometric investigations on two morphologically differing titanium surfaces with and without fluorohydroxyapatite coating: an experimental study in sheep tibiae. Biomaterials 2003; 24:3183-92. [PMID: 12763445 DOI: 10.1016/s0142-9612(03)00164-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The influence of fluorohydroxyapatite (FHA) coating and surface roughness of Ti6Al4V implants on bone response was investigated. Uncoated and FHA-coated screws with lower (LR and LR+FHA; Ra: 5.7+/-0.2 microm) and higher (HR and HR+FHA; Ra: 21.8+/-0.9 microm) surface roughness, were inserted into the diaphyses of 8 sheep tibiae. Twelve weeks after implantation, extraction torque and bone-to-implant contact were evaluated. The smoothest surfaces showed an improved extraction torque and significant differences were observed between LR and HR (-24.6%, p<0.0005), LR and HR+FHA (-30.7%, p<0.0005), LR+FHA and HR (-17.4%, p<0.005), and LR+FHA and HR+FHA (-24.0%, p<0.005). The bone-to-implant contact data paralleled the biomechanical data: the smoother the surface, the greater the bone-to-implant contact. Significant (p<0.0005) decreases in bone-to-implant contact were observed between LR+FHA and HR (-24.2%), and between LR+FHA and HR+FHA (-29.2%). The current findings suggest that LR surfaces significantly improve the osteointegration rate of implanted cortical screws independently of the FHA coating.
Collapse
Affiliation(s)
- M Fini
- Experimental Surgery Department, Codivilla-Putti Research Institute, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, 40136 Bologna, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Landar A, Curry B, Parker MH, DiGiacomo R, Indelicato SR, Nagabhushan TL, Rizzi G, Walter MR. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma. J Mol Biol 2000; 299:169-79. [PMID: 10860730 DOI: 10.1006/jmbi.2000.3734] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized. IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue. Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM. The crystal structure of IFN-gamma SC1 has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6. Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of IFN-gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials. As a result, surface charge rather than structural changes is likely responsible for the inability of the His111-->Asp domain of to bind IFN-gamma R alpha. The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex. Thus, IFN-gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested. The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures. Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays. This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity. The current data are consistent with the main role of the IFN-gamma dimer being to decrease the dissociation constant of IFN-gamma for its cellular receptors.
Collapse
Affiliation(s)
- A Landar
- Center for Macromolecular Crystallography, University of Alabama, Birmingham 35294, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Feola M, Boffano GM, Procopio M, Reynaud S, Allemano P, Rizzi G. Ambulatory 24-hour blood pressure monitoring: correlation between blood pressure variability and left ventricular hypertrophy in untreated hypertensive patients. G Ital Cardiol 1998; 28:38-44. [PMID: 9493044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Left ventricular hypertrophy (LVH) appears to be poorly correlated with clinical measurements of blood pressure: a better correlation may be observed with data from 24 h ambulatory blood pressure monitoring (ABPM). The aim of this study was to compare the results of non-invasive ABPM in a population of patients with essential hypertension who had never been treated, subdividing them based on the presence or absence of LVH in the transthoracic echocardiogram (LVMI, left ventricular mass index > 135 g/m2 in males and > 110 g/m2 in females). METHODS Eighty hypertensive patients with mild or moderate hypertension underwent routine blood tests, a 24 h ABPM and a transthoracic echocardiogram. Based on the ABPMs, we analyzed average 24 h systolic and diastolic blood pressure (BP), average daytime (6 a.m.-10 p.m.) and nighttime (10 p.m.-6 a.m.) systolic and diastolic BP, average morning (6-12 a.m.) BP and the number of dipper or non-dipper patients. The echocardiographic study included the calculation of left ventricular mass using Devereux's formula according to the Penn convention, analysis of the patterns of left ventricular geometry and a study of left ventricular diastolic function. RESULTS Thirty-five (43.7%) patients had LVH at the echocardiographic study. In 52 subjects, the clinical history showed at least one BP measurement > 140/90 mmHg in the year prior to our observation. The average age was 48 +/- 11, without any significant correlation to LVMI (r = 0.13). The magnitude of the S-wave in V1 and the R-wave in V5 and the magnitude of the tallest R-wave and S-wave in the electrocardiogram analysis had a significant correlation with LVMI (r = 0.23 and r = 0.26, respectively). The echocardiogram revealed a normal left ventricular geometry in 43.8% of hypertensive patients, concentric remodeling in 13.8%, concentric hypertrophy in 16.2% and eccentric hypertrophy in 26.2%. The isovolumic relaxation time (IVRT) and A-wave were significantly correlated with LVMI (r = 0.49 and r = 0.33, respectively). LVMI had a significant correlation with systolic BP at ABPM (24 h systolic BP r = 0.34; daytime systolic BP r = 0.35; nighttime systolic BP r = 0.28; 6-12 systolic BP r = 0.29) but not with diastolic BP. Dipper patients represented 76.3% of the population, without any difference in LVMI between dippers and non-dippers (p = 0.09). Dipper patients had a higher prevalence of normal left ventricles as compared with non-dippers (p < 0.0001). White-coat hypertension was observed in 7.5% of hypertensive patients. CONCLUSIONS The prevalence of LVH in our population was high (43.7%) and some parameters related to diastolic left ventricular function (IVRT, A-wave) were correlated with LVMI. Systolic ambulatory BP was significantly correlated with LVMI, while diastolic BP was not.
Collapse
Affiliation(s)
- M Feola
- Servizio di Cardiologia, Azienda Ospedaliera USL 17, Ospedale Civile, Saluzzo, CN
| | | | | | | | | | | |
Collapse
|
30
|
Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol 1996; 135:407-12. [PMID: 8921821 DOI: 10.1530/eje.0.1350407] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The function of the growth hormone-insulin-like growth factor I (GH-IGF-I) axis is reduced in aging, although the secretory capacity of somatotrope cells is preserved. Previous studies have suggested that continuous administration of GH-releasing peptides (GHRPs) results in homologous desensitization to the GH-releasing effect of the peptides. In the present study we have studied whether healthy elderly subjects would remain responsive to short-term, intermittent treatment with Hexarelin (HEX), a GHRP, and whether this treatment would result in an increase in serum IGF-I. In study I, the effect of an 8-day treatment with intranasal administration of 1.25 mg (about 18 micrograms/kg) t.i.d. HEX on the acute GH response to the hexapeptide and on serum IGF-I, IGF binding protein 3 (IGFBP-3), prolactin and cortisol levels was studied in seven elderly subjects (four males and three females, aged 67-80 years). In study II, the same parameters were studied before and after a 15-day treatment with oral administration of 20 mg (about 300 micrograms/kg) t.i.d. HEX in seven elderly women (aged 63-80 years). The GH response to the intranasal HEX administration was not significantly higher than that induced by 1 microgram/kg iv GHRH (229.4 +/- 35.9 vs 145.8 +/- 26.9 micrograms.l-1.h-1) and was maintained with a trend towards increase after an 8-day treatment with the peptide (342.5 +/- 199.3 micrograms.l-1.h-1). On the other hand, HEX treatment did not significantly modify IGF-I (138.7 +/- 11.1 vs 122.4 +/- 14.1 micrograms/l) but increased IGFBP-3 levels (2.4 +/- 0.2 vs 1.6 +/- 0.2 mg/l, p < 0.02). The GH response to the oral HEX administration was also not significantly higher than that to iv GHRH (257.6 +/- 72.0 vs 179.0 +/- 42.8 micrograms.l-1.h-1) and did not change after a 15-day treatment with the peptide (237.8 +/- 42.8 micrograms.l-1.h-1). Both IGF-I and IGFBP-3 levels were slightly but significantly increased by oral HEX treatment (156.0 +/- 10.7 vs 141.6 +/- 13.6 micrograms/l, p < 0.03, 3.4 +/- 0.2 vs 3.1 +/- 0.2 mg/l, p < 0.03, respectively). Neither intranasal nor oral HEX treatment modified PRL or cortisol levels and did not induce any side effect. In conclusion, these results indicate that chronic but intermittent treatment with HEX, administered either by intranasal or oral route, does not desensitize the GH response to the peptide. Moreover, after HEX treatment a trend towards increase was shown for IGF-I and IGFBP-3 levels. Thus, our findings strengthen the hypothesis that prolonged treatment with HEX may restore the reduced GH release in aging.
Collapse
Affiliation(s)
- E Ghigo
- Division of Endocrinology, University of Turin, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Rizzi G. Pyoderma gangrenosum appeared after cutaneous surgery in a chronic HCV hepatitis's patient. J Eur Acad Dermatol Venereol 1995. [DOI: 10.1016/0926-9959(95)96344-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Rizzi G. Disseminated granuloma annulare in a patient with transitory hyperthyroidism. J Eur Acad Dermatol Venereol 1995. [DOI: 10.1016/0926-9959(95)96355-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Diegele E, Munz D, Rizzi G. Design and life assessment of first wall components. Fusion Engineering and Design 1995. [DOI: 10.1016/0920-3796(95)90129-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Grasso R, Rizzi G, Schena F, Cevese A. Arterial baroreceptors are not essential for low frequency oscillation of arterial pressure. J Auton Nerv Syst 1995; 50:323-31. [PMID: 7714326 DOI: 10.1016/0165-1838(94)00103-q] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Cardiovascular parameters exhibit spontaneous oscillations at the respiratory frequency, and in the low frequency range (LF < 0.20 Hz). Although LF is attributed to the sympathetic control, the mechanism responsible for the oscillation, whether instability of the baroreflex loop, or activity of a central nervous system pattern generator, is controversial. To answer this question, time series of arterial blood pressure, heart period and left external iliac blood flow from chloralose-anaesthetised dogs were examined by standard statistics as well as by autoregressive spectral and cross-spectral analysis. The circulation to the left hind-limb was isolated and connected to a constant-pressure perfusing system, to obtain mechanical uncoupling from the central circulation. Three steady-state conditions were studied. A device inserted into the common carotid arteries allowed the carotid sinus region to be in continuity with the animal's arterial system (CONTROL) or perfused at constant pressure by an external source (CAROTID BUFFER); bilateral cervical vagotomy was also performed (VAGI CUT). Intra-individual (beat-to-beat) variability of each parameter was evaluated by standard deviation (SD) of time series in the three conditions. The average SD of heart period was reduced in CAROTID BUFFER and in VAGI CUT; the SDs of arterial pressure and iliac flow were not changed by these interventions. Autospectra of iliac flow time series in CONTROL showed a prominent peak at 0.05 +/- 0.04 Hz (mean +/- SD of all experiments), accounting for 90 +/- 11% of the total variance.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R Grasso
- Institute of Human Physiology, University of Verona, Italy
| | | | | | | |
Collapse
|
35
|
Ghigo E, Arvat E, Rizzi G, Goffi S, Grottoli S, Mucci M, Boghen MF, Camanni F. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol 1994; 131:499-503. [PMID: 7952160 DOI: 10.1530/eje.0.1310499] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The reduced activity of the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis in aging may contribute to changes in body composition. As this GH insufficiency is due to hypothalamic pathogenesis, the availability of GH-releasing peptides (GHRPs), such as GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) which is active even after oral administration, might be useful to restore it. The aim of our study was to verify the effectiveness of oral administration of GHRP-6 in normal elderly subjects and to investigate whether its GH-releasing activity is maintained or vanishes after short-term oral treatment. Seven normal elderly women (aged 65-82 years) were studied. The effect of oral administration of 300 micrograms/kg GHRP-6 on GH secretion was investigated before and after 4 days of treatment with the hexapeptide given twice daily. The GH response to the maximal effective dose of GHRH (1 microgram/kg i.v.) also was studied. Before treatment, oral administration of 300 micrograms/kg GHRP-6 elicited a clear GH rise (peak 10.7 +/- 3.3 micrograms/l; AUC 353.1 +/- 90.6 micrograms.l-1.h-1), which was significantly higher (p < 0.01) than that induced by intravenous GHRH (peak 5.1 +/- 1.5 micrograms/l; AUC 106.5 +/- 43.9 micrograms.l-1.h-1). After 4 days of treatment with GHRP-6, the GH response to the hexapeptide was maintained, with a trend towards an increase (peak 16.8 +/- 2.9 micrograms/l; AUC 499.8 +/- 107.2 micrograms.l-1.h-1). The IGF-I levels were not increased significantly after treatment (77.1 +/- 8.4 vs 84.1 +/- 12.2 micrograms/l).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- E Ghigo
- Department of Pathophysiology, University of Turin, Italy
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994; 17:157-62. [PMID: 8051337 DOI: 10.1007/bf03347707] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In man the GH-releasing hexapeptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 (GHRP-6) has been shown to be active even after oral administration. On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Based on the foregoing, in this study we verified the GH-releasing activity of oral GHRP-6 (300 micrograms/kg) in normal aging and the possible enhancing effect of 8 g oral ARG on the GH-releasing effect of GHRP-6. Eight young (age 24-32 yr) and 8 elderly (age 66-85 yr) subjects were studied. In all the GH response to GHRH (1 microgram/kg iv) was also studied. Both IGF-I levels and the GH response to iv GHRH were lower in elderly than in young subjects (mean +/- SE, IGF-I: 65.1 +/- 9.1 vs 142.9 +/- 9.4 micrograms/L, p < 0.0001; GH peak: 5.4 +/- 1.0 vs 13.6 +/- 0.8 micrograms/L, p < 0.0001). Oral GHRP-6 administration induced a GH rise in elderly which was lower, though not significantly, than that in young subjects (GH peak: 9.9 +/- 2.0 vs 16.2 +/- 5.4 micrograms/L). Oral ARG administration enhanced the GHRP-6-induced GH rise in elderly (GH peak: 22.1 +/- 3.3 micrograms/L, p < 0.01 vs GHRP-6 alone) while failed to modify it in young subjects (GH peak: 13.5 +/- 3.4 micrograms/L). The GH response to oral ARG+GHRP-6 in elderly was higher than that to all stimuli in young adults (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- E Ghigo
- Dipartimento di Fisiopatologia Clinica, Università di Torino, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Serra GC, Capozzi MP, Toppino M, Enrico S, Tini E, Rovere V, Rizzi G, Scorza V, Fronda GR. [Carcinoma of the parathyroid glands. Apropos of a case associated with thyroid struma]. MINERVA CHIR 1990; 45:903-6. [PMID: 2250789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The paper reports a case of carcinoma of the parathyroid associated with thyroid struma and underlines the difficulties of intraoperative diagnosis and the surgical approach which should be adopted on the basis of this finding. Often the diagnosis of the malignant nature of the neoplasia is based on the possible appearance of local or distant recurrence rather than histological examination.
Collapse
Affiliation(s)
- G C Serra
- Istituto di Clinica Chirurgica Generale, Università degli Studi di Torino
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Patrone P, Passarini B, Rizzi G. [Laugier-Hunzicker syndrome. Description of 3 clinical cases]. Dent Cadmos 1990; 58:83-5. [PMID: 2397835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
39
|
|
40
|
Rizzi G. [Treatment of hypopituitarism]. MINERVA ENDOCRINOL 1990; 15:43-54. [PMID: 2274014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The hipopituitarim's treatment is in want to use the hormonal replacement with corticosteroid and l-tiroxine in all patients. The exogenous gonadotropin or sexual hormones are administrated in both sexes in different way for different ages. The pituitary dwarfism secondary to GH deficiency is now cured with the syntetic GH use. The DDAVP is the drug of choice in the therapy of diabetes insipidus.
Collapse
Affiliation(s)
- G Rizzi
- Dipartimento di Fisiopatologia Clinica, Università di Torino
| |
Collapse
|
41
|
Avataneo T, Potenzoni F, Cesarani F, Isaia GC, Rizzi G. [Comparison of MR and CT in a radiological study of Cushing's syndrome. A report on 16 cases]. Minerva Med 1990; 81:1-4. [PMID: 2314610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In 16 patients with high cortisol plasma levels MRI and CT investigation of adrenal gland region was performed; 13 also had the pituitary region examined. CT and MRI results in Cushing's Syndrome due to adrenal glands etiology (8 cases) are overlapping. The morphological criteria utilized consist in the radiological finding of bilateral adrenal hyperplasia or adrenal mass (adenoma, carcinoma). The great amount of retroperitoneal fat increases the normal contrast with both techniques. In the pituitary Cushing's Syndrome MRI was more sensible than CT as far as it concerns ACTH producing pituitary lesion assessment; this technique may show 5 mm diameter adenomas for their high signal intensity.
Collapse
Affiliation(s)
- T Avataneo
- Università di Torino, Istituto di Radiologia
| | | | | | | | | |
Collapse
|
42
|
Gulinati AM, Rizzi G, Bianchi A, Scopetta V, Salvatorelli G. [Normal human gingiva. In vitro observations]. Dent Cadmos 1989; 57:90-1. [PMID: 2641385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
By comparing human embrional gum fragments cultivated in vitro using the technique of Wolff and Haffen with adult gum fragments, the advantages of the fetal gum are evident; and this could serve as a point of departure for an analysis of the differentiation and the cytophysiology of this structure, which is still not very well known.
Collapse
|
43
|
Checchi L, Pelliccioni GA, Rizzi G. [Control of postoperative pain in periodontology]. Dent Cadmos 1989; 57:107-11. [PMID: 2636180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In periodontal surgery 2 long acting local anaesthetics, Bupivacaine and Etidocaine, have been compared to Mepivacaine and Lidocaine with regard to effect upon the immediate postoperative pain. Both long acting solutions were significantly superior to Lidocaine and Mepivacaine.
Collapse
|
44
|
Limone P, Pogliano G, Castellano G, Argirò G, Isaia GC, Favero A, Cottino F, Rizzi G, Molinatti GM. 131-I-meta-iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma. Panminerva Med 1988; 30:169-72. [PMID: 3211575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
45
|
Ghigo E, Mazza E, Imperiale E, Rizzi G, Benso L, Müller EE, Camanni F, Massara F. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature. J Clin Endocrinol Metab 1987; 65:452-6. [PMID: 3114300 DOI: 10.1210/jcem-65-3-452] [Citation(s) in RCA: 32] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Increased cholinergic tone induced by pyridostigmine (PD) increases basal plasma GH levels and potentiates the GH response to GHRH in normal adults. In this study the effects of PD (60 mg, orally) on both basal and GHRH (1 microgram/kg)-induced GH secretion in seven children with familial short stature (FSS), six with GH deficiency (GHD) and 10 with constitutional growth delay (CGD) were studied and compared with results obtained by stimulation with insulin-induced hypoglycemia (IH) and GHRH alone. The mean peak plasma GH levels were variable, but individual values were frequently low in all groups after both IH [FSS, 9.7 +/- 1.3 (+/- SEM) ng/mL; GHD, 1.6 +/- 0.4 ng/mL; CGD, 7.0 +/- 0.8 ng/mL] and GHRH (FSS, 23.8 +/- 6.6 ng/mL; GHD, 11.1 +/- 5.8 ng/mL; CGD, 15.1 +/- 4.5 ng/mL) administration. PD induced GH responses (FSS, 14.5 +/- 1.6 ng/mL; GHD, 3.8 +/- 0.8 ng/mL; CGD, 18.3 +/- 3.2 ng/mL) that in many children in the FSS and CGD groups were higher than those after IH and GHRH treatment. PD clearly increased the GH response to GHRH in all children [FSS, 69.5 +/- 9.4 ng/mL (P less than 0.01 vs. other stimuli); GHD, 18.0 +/- 7.5 ng/mL; CGD, 50.0 +/- 8.5 ng/mL (P less than 0.01 vs. other stimuli)]. We conclude that in children with short stature, as in adults, enhancement of cholinergic tone increases both basal and GHRH-induced GH secretion, and that PD plus GHRH is the best provocative stimulus for evaluating the somatotroph response.
Collapse
|
46
|
Ciccarelli E, Ghigo E, Mazza E, Gandini G, Avataneo T, Rizzi G, Bertagna A, Camanni F. Pituitary computed tomography and dynamic tests of prolactin and thyrotropin secretion in 103 hyperprolactinemic patients. Panminerva Med 1987; 29:195-202. [PMID: 3696753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
47
|
Rizzi G, Argiró G, Gentile L, Castellano G, Brossa C, Borré A. Use of the thyroid 99Tcm scintiscan with lead-shield on the hot nodule in the diagnosis of autonomous adenoma. Nucl Med Commun 1987; 8:217-20. [PMID: 2825088 DOI: 10.1097/00006231-198704000-00007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Eighteen patients bearing a hot nodule, imaged by basal 99Tcm scintiscan and toxic in eight of them, were studied. All patients underwent 99Tcm thyroid scintiscan in basal conditions and after placing a lead-shield on the hot thyroid nodule, without other radioisotope administration. In eight cases the thyroid scintiscan after lead-shield overlapping the hot nodule, was compared to a second 99Tcm thyroid scintiscan after thyrotrophic hormone stimulation, TSH. This technique of nodule shielding was able to show the extranodular tissue in 15 patients; in the remaining three cases neither this approach nor the scintiscan after exogenous TSH were able to demonstrate any remainder thyroid parenchyma. Thus, this scintigraphic method can be considered excellent in the diagnosis of autonomous adenoma: it needs, in fact, a single radioisotope administration and does not present the adverse effects frequently induced by exogenous TSH.
Collapse
Affiliation(s)
- G Rizzi
- Dipartimento di Biomedicina Endocrinometabolica e Gastroenterologica, University of Turin, Italy
| | | | | | | | | | | |
Collapse
|
48
|
Abstract
A case of acromegaly is reported, in which pituitary apoplexy had occurred immediately after computed tomographic examination of the sellar region, followed by recovery from the disease and partial hypopituitarism. The possible mechanisms underlying this event are discussed.
Collapse
|
49
|
Moretti O, Milani M, Rizzi G, Bresciani E, Verri B. [Supplemental and total parenteral nutrition in assisting the very small premature infant]. Minerva Pediatr 1984; 36:989-96. [PMID: 6442394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
50
|
Garsia S, Rizzi G, Re MP, Zamberletti D, Remotti G. [Lasers in uterine microsurgery: experimental research]. Ann Ostet Ginecol Med Perinat 1984; 105:171-85. [PMID: 6497230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|